ISPOR Europe 2023

Share on:

Sunday, November 12 - Wednesday, November 15, 2023

HEOR at the Nexus of Policy and Science

Many of our researchers will be in Copenhagen and would love to chat with you. You can find them at the RTI Health Solutions exhibitor booth and in many of the presentations. Ask them how Health Solutions can help you with a unified approach to your development strategies as well as provide rigorous and reliable research for your HEOR needs.

Let's get to know each other better - stop by our booth at C3-045 in the Bella Center.

Presentations & Preconference Courses

12 November, 8:00-12:00

Short Course 005

Estimating health-state utility for economic models in clinical trials and real-world studies. Doward L, Hawe E, Lloyd A, Wolowacz S.

Course faculty: Lynda Doward, Emma Hawe, Sorrel Wolowacz

12 November, 8:00-12:00

Short Course 001

Budget impact analysis I: a 6-step approach. Earnshaw S, Brodtkorb T-H, Mullins D.

Course faculty: Stephanie Earnshaw, Thor-Henrik Brodtkorb

12 November, 13:00-17:00

Short course 011

Budget impact analysis II: applications and design issues. Brodtkorb T-H, Brogan A, Davis A, Earnshaw S.

Course faculty: Thor-Henrik Brodtkorb, Anita Brogan, Ashley Davis, Stephanie Earnshaw

13 November, 15:00-16:00

Framework Update 134

Professional competencies for health economics and outcomes research – 2023 update to the ISPOR Competencies Framework. Onukwugha E, Earnshaw S, Pizzi L, Shukla S.

Speaker: Stephanie Earnshaw

14 November, 17:00 - 18:00

Podium Presentations 255

Open-source model framework for health-economic evaluation of early treatment in Alzheimer's disease. Handels R, Wimo A, Skoldunger A, Tate A, Winblad B, Silvertand D, Nguyen L, Jonsson L, Grimm S, Aye S, Herring W.

P3 17:30 - 17:45

Moderator: Thor-Henrik Brodtkorb

15 November, 8:00-9:00

Case Studies 307

HTA Case Studies II

Moderator: Sorrel Wolowacz

15 November, 10:00-11:00

Breakout Session 315

The FINOSE collaboration – joint health technology assessment in the Nordics. Eriksson M, Andersson Galijatovic E, Schiel A, Brodtkorb T-H.

Discussion leader: Thor-Henrik Brodtkorb

Poster Session 1, 13 November 10:30-13:30

MT13

Digging into the medical technology HTA process in Tunisia. doi: 10.1016/j.jval.2023.09.2242Mordin M, Warttig S, Gildea L, Long J, D'Souza V, Kinderås M, Ling C, Hartley L.

PCR47

Consumer preferences for attributes of influenza vaccines in the United States: results from a discrete-choice experiment study. doi: 10.1016/j.jval.2023.09.2486Poulos C, Leach CA, Kent C, Rudin D, Buck P, Ghaswalla P.

Poster Session 2, 13 November 15:30 - 18:30

CO69

Evidence gap analysis of the burden of illness and treatment of bullous pemphigoid. doi: 10.1016/j.jval.2023.09.141Gildea L, Copley-Merriman C, Arvin-Berod C, Vande Walle K, Verheesen P, Stoykov I.

EE225

Exploring the value of country-specific cost-effectiveness models in early stages of drug development. doi: 10.1016/j.jval.2023.09.493Ronquest N, Paret K, Mladsi DM, Lee LJ.

MSR39

The performance of anchored and unanchored population adjustment methods (matching-adjusted indirect comparison, simulated treatment comparison, and multiple imputation marginalization) in castration resistant prostate cancer. doi: 10.1016/j.jval.2023.09.2098Vickers A.

Discussion period: 16:00 - 17:00

MSR60

Use of external control arms (ECAs) in marketing applications submitted to European medicines agency (EMA): a targeted review. doi: 10.1016/j.jval.2023.09.2119Houghton K, Nangia A, Hawe E.

Discussion period: 16:00-17:00

MT25

What evidence should medical technology companies expect HTA bodies to review? doi: 10.1016/j.jval.2023.09.2254Mordin M, Gildea L, Long J, D'Souza V, Kinderås M, Ling C, Warttig S, Hartley L.

MT29

Understanding how health technology assessment bodies select medical technology for review: results of an online survey. doi: 10.1016/j.jval.2023.09.2258Gildea L, Mordin M, Long J, D'Souza V, Kinderås M, Warttig S, Hartley L, Ling C.

PCR87

Collecting exploratory patient preference data using an efficient approach: an example in rare diseases. doi: 10.1016/j.jval.2023.09.2526Ho KA, Pierce A, Stoltenberg M, Tarancon T, Mansfield C.

Poster Session 3, 14 November 10:30 - 13:30

EE355

Pre-progression health state utility values from the TALAPRO-2 clinical trial in patients with metastatic castration-resistant prostate cancer with HRR mutations. doi: 10.1016/j.jval.2023.09.772Niyazov A, Simou E, Kirker M, Houghton K, Le Moine JG, Chang J, Yarr S, Barnett C, Mladsi D.

EE439

Public health impact of the pediatric immunization program in the Netherlands. doi: 10.1016/j.jval.2023.09.705Cook C, Carrico J, Talbird S, Sabale U, Dolk C, Bencina G.

MSR72

The impact of life expectancy exclusion criteria on survival curve extrapolation. doi: 10.1016/j.jval.2023.09.2131Vickers A, Leng X.

Discussion Period: 12:30 - 13:30

MT43

Does real-world evidence play a role in decision-making by HTA bodies for medical technologies? doi: 10.1016/j.jval.2023.09.2271Hartley L, Gildea L, Mordin M, Long J, D'Souza V, Kinderås M, Ling C, Warttig S.

MT44

Submission process and requirements of Nordic health technology assessment organisations for medical technologies: results of an online survey. doi: 10.1016/j.jval.2023.09.2272Kinderås M, Gildea L, Mordin M, Long J, D'Souza V, Ling C, Warttig S, Hartley L.

PT27

How much does TLV value rarity? A review of reimbursement decisions on orphan drugs in Sweden from 2017 through 2022. doi: 10.1016/j.jval.2023.09.1028Lanne G, Kinderås M, Ling C, Brodtkorb TH.

SA44

Clinical burden of patients with moderate-to-severe chronic obstructive pulmonary disease: a focused literature review. doi: 10.1016/j.jval.2023.09.2953Mayen Herrera E, Chiranjeevi P, Stanford R, Njue A, Lyall M, Nuabor W, D'Souza V, Dubucq H, Moola S.

Poster Session 4, 14 November 15:30-18:30

CO117

Prognostic factors and surrogate endpoints in obstructive hypertrophic cardiomyopathy: a systematic literature review. doi: 10.1016/j.jval.2023.09.189Krause T, Fleming A, Hurst M, Zema C, Costello J, Hawe E, Ling C.

EE507

Pre-progression health state utility values from the TALAPRO-2 clinical trial in patients with metastatic castration-resistant prostate cancer unselected for DDR mutations. doi: 10.1016/j.jval.2023.09.772Niyazov A, Simou E, Kirker M, Houghton K, Le Moine JG, Chang J, Yarr S, Barnett C, Mladsi D.

HSD102

Preferences of nurses for attributes of pediatric hexavalent vaccines in the United Kingdom. doi: 10.1016/j.jval.2023.09.1653Boeri M, Marcek T, Chintakayala PK, Poulos C, Francis A, Langevin E, Balogh O, Petigara T, O’Connor J, Samant S.

MSR121

Use of external control arms in pharmaceutical submissions to the national institute for health and care excellence for technology appraisals: a targeted review. doi: 10.1016/j.jval.2023.09.2180Nangia A, Houghton K, Hawe E.

Discussion period: 16:00-17:00

MT61

Differences and similarities of health economic evaluation for medical technologies by HTA bodies. doi: 10.1016/j.jval.2023.09.2287D'Souza V, Gildea L, Mordin M, Long J, Kinderås M, Ling C, Warttig S, Hartley L.

PCR181

Health-related quality-of-life of patients treated with repotrectinib for neurotrophic tyrosine receptor kinase (NTRK)-positive advanced solid tumors: results From TRIDENT-1. doi: 10.1016/j.jval.2023.09.2619Sherif B, Burke M, Besse B, Solomon B, Bazhenova L, Kim DW, Lin JJ, Wolf J, Popat S, Goto K, de Langen AJ, Springfeld C, Reynolds M, Odom D, Yuan Y, Lee A, Blum SI, Thamake S, Ades F, Drilon A.

Presenting author: Bintu Sherif

PCR212

A novel approach to capturing real-world reasons behind use and satisfaction of NVX-CoV2373 booster use among German adults: direct-to-patient enrollment. doi: 10.1016/j.jval.2023.09.2649Calhoun S, Kutikova L, Hollis KA, Helme K, Miller A, Schwarz TF.

Discussion period: 16:00-17:00

SA61

Economic burden of patients in the United States with moderate-to-severe chronic obstructive pulmonary disease: a focused literature review. doi: 10.1016/j.jval.2023.09.2970Mayen Herrera E, Chiranjeevi P, Stanford R, Njue A, Lyall M, Nuabor W, D'Souza V, Dubucq H, Moola S.

Poster Session 5, 15 November 9:00 - 11:30

EE730

Discussion period: 9:00 - 10:00

EE744

Invasive meningococcal disease economic burden: a comprehensive analysis. doi: 10.1016/j.jval.2023.09.1009Langevin E, Lesage H, Juniper M.

HPR184

Social Determinants of Health (SDoH) and other predictors in treatment initiation with CDK4/6 inhibitors in Medicare patients with HR+/HER2– Metastatic Breast Cancer (MBC). doi: 10.1016/j.jval.2023.09.1502Goyal RK, Candrilli SD, Abughosh SM, Chen H, Holmes HM, Johnson ML.

Discussion period: 9:00 - 10:00

HSD128

Preferences of healthcare providers in Switzerland for attributes of pediatric hexavalent vaccines. doi: 10.1016/j.jval.2023.09.1679Samant S, Oberle S, Marcek T, Poulos C, Chintakayala PK, Langevin E, Petigara T, Boeri M.

MSR136

IPECAD modeling workshop 2023 cross comparison challenge on cost-effectiveness models in Alzheimer's disease and related dementias. doi: 10.1016/j.jval.2023.09.2194Handels R, Herring W, Kamgar F, Gustavsson A, Skoldunger A, Wimo A, Tate A, Winblad B, Stellick CB, Bruck C, Green C, de Kok I, Hlavka J, Mar J, Urbich M, Soto-Gordoa M, Pemberton-Ross P, Aye S, Jonsson L, workshop 2023 Participants I.

PCR260

Influence of disease activity and angioedema on EQ-5D-5L utility scores in chronic spontaneous urticaria. doi: 10.1016/j.jval.2023.09.2697Hawe E, Simou E, Balp MM, Kohli R, Wiyani A.

Meet our experts at ISPOR

Susan Barker, BA

Senior Director, Marketing-Digital Strategy

Contact

James Brockbank, MSc

Director, Health Economics

Contact

Thor-Henrik Brodtkorb, PhD

Executive Director, Health Economics

Contact

Anita Brogan, PhD

Vice President, Decision Analytic Modeling, Health Economics

Contact

Rebecca Crawford, MA

Director, Patient-Centered Outcomes Assessment

Contact

Ashley Davis, PhD

Senior Director, Health Economics

Contact

Jennifer Dine, PhD, RN

Director, Patient-Centered Outcomes Assessment

Contact

Frank Distler, MSc

Senior Director, Business Development

Contact

Lynda Doward, MRes

VP, European Head Patient-Centered Outcomes Assessment

Contact

Stephanie Earnshaw, PhD

Senior Vice President, Health Economics

Contact

Liesl Gildea, MSc

Associate Director, Market Access and Outcomes Strategy

Contact

Ari Gnanasakthy, MBA, MSc

Principal Scientist, Patient-Centered Outcomes Assessment

Contact

Louise Hartley, PhD

Senior Director, Evidence Synthesis and Statistics

Contact

Emma Hawe, MSc

Head, Data Analytics and Design Strategy

Contact

Kelly Hollis, MBA

Vice President, Surveys and Observational Studies

Contact

Katie Houghton, MSc

Director, Health Economics

Contact

Maria Kinderås, MSc

Associate Director, Market Access and Outcomes Strategy

Contact

Jean-Gabriel Le Moine, MS

Director, Evidence Synthesis and Statistics

Contact

Caroline Ling, PhD

Executive Director and HTA Specialist, Market Access and Outcomes Strategy

Senior Economist

Associate Director, Business Development

Contact

Christine Poulos, PhD

Senior Economist and Vice President, Health Preference Assessment

Contact

Maria Reynolds, MStat

Senior Statistician

Contact

Sarah Sauchelli Toran, PhD

Senior Researcher, Patient-Centered Outcomes Assessment

Senior Statistician

Director, Patient-Centered Outcomes Assessment

Senior Economist

Senior Director, Evidence Synthesis and Statistics

Contact

Sheryl Warttig, DHealthPsy

Director, Market Access and Outcomes Strategy

Contact

Diane Whalley, PhD

Executive Director, Patient-Centered Outcomes Assessment

Contact

Peter Wirth, BS

Vice President, Business Development

Contact

Sorrel Wolowacz, PhD

Head, European Health Economics

Contact

Video Transcript

In recent years, an increasing number of medical technologies such as devices, diagnostics, and digital health technologies have been evaluated through various health technology assessment (HTA) frameworks around the world.

Because assessment by HTA organizations is still evolving, there is a lack of harmonization among various agencies on process and methods. Information may seem unclear - particularly the requirements for economic evaluations - making planning for submissions difficult for companies developing these technologies.

To address this, we developed an online survey requesting information from various HTA agencies on their key health economic evaluation metrics.

Our results show that there are differences and similarities among the various HTA organizations, in aspects such as topics covered in the economic systematic literature reviews, type of economic evaluations considered, perspectives used, discounting rates used for cost and outcomes, and willingness-to-pay thresholds. Economic assessment is linked to national contexts and understanding these key differences and similarities is essential if companies are to demonstrate economic benefits efficiently and achieve market-access objectives for their products.

Learn more by viewing the research.

Differences and similarities of health economic evaluation for medical technologies by HTA bodies

Video Transcript

While health technology assessments, or HTAs, of pharmaceutical products have existed for a while, HTA organizations have in recent years taken medical technologies under their wings as well. Nordic countries submissions are often grouped together for efficiency. However, the assessment of medtech is a developing area, and there is no current consensus on methods.

We conducted a study to assess the range of medtech processes and requirements in Nordic countries. We developed an online survey for Nordic HTA organizations requesting information on the selection process, general submissions process, and types of evidence considered part of the clinical and economic assessment.

We discovered that there are many similarities between the organizations that could provide efficiencies. However, medtech companies must be aware of the differences – especially in the selection process – that will impact evidence generation needs and submission planning.

Learn more about this research by viewing the results.

Submission process and requirements of Nordic HTA organizations for medical technologies

Video Transcript

In this study, we identified challenges in designing conceptual models for biologic therapies in eosinophilic-associated diseases.

We performed a targeted search of the Embase database and health technology assessment agency websites to identify examples of cost-effectiveness modeling. The model structures often included health states defined by levels of disease and treatment response. However, vague definitions of disease control and a lack of consensus on treatment response posed a challenge in evaluating comparative treatment efficacy. Other challenges included understanding long-term treatment efficacy, identifying appropriate treatment stopping rules, finding publications reporting stratified cost and utility estimates, and difficulty quantifying the costs and disutility of long-term steroids use.

We recommend early engagement with clinical experts and payers is recommended for reaching a consensus on positioning biologics and creating clear definitions of disease control and treatment response. Further research on resource use and utility associated with different levels of disease activity is needed.

Modelling considerations for evaluating the cost-effectiveness of biologics

ISPOR Europe 2023

Enter our book giveaway

HEOR at the Nexus of Policy and Science

Meet our experts at ISPOR